Results 41 to 50 of about 30,408 (190)
Bedaquiline in the treatment of extensively drugresistant tuberculosis
Медицинский совет, 2022 Introduction. Extensive drug resistance (XDR) M. Tuberculosis (MBT) is considered the main factor that reduces the effectiveness of the treatment of TB patients around the world, including Russia.
T. I. Morozova +3 more
doaj +1 more source
In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
, 2019 <p>Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown.
A. Martin +11 more
core +1 more source
Advanced Science, EarlyView.Cloperastine suppresses osteoclastogenesis by inhibiting PGC1β‐mediated oxidative phosphorylation. Its incorporation into a ROS‐responsive, Asp8‐modified nanoplatform enhances skeletal accumulation. The resulting Clo/Asp8‐PMK‐MCs combine cloperastine‐mediated antiresorptive activity with carrier‐mediated osteogenic activity to attenuate OVX‐induced ...
Haibo Liang +16 more
wiley +1 more source
Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access
Clinical Pharmacology &Therapeutics, EarlyView.Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian +5 more
wiley +1 more source
, 2019 Indications for the use of bedaquiline, second line drug susceptibility test results when bedaquiline was started, and the resulting changes in regimen among patients who received bedaquiline (n = 76).
Leonie Van Zyl (7512503) +8 more
core +1 more source
Bedaquiline: what might the future hold? [PDF]
Tuberculosis drug development has stagnated for decades, so the recent availability of bedaquiline is welcome. Bedaquiline-containing regimens, now the first-line therapy recommended by WHO, have transformed the treatment of drug-resistant tuberculosis ...
Shaw, Emily S +19 more
core +4 more sources
PLOS Global Public Health, 2023 Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of ...
Juliano Timm +9 more
doaj +1 more source
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies
Medicinal Research Reviews, EarlyView.ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva +23 more
wiley +1 more source
Tropical Medicine &International Health, EarlyView.ABSTRACT Tuberculosis remains a major public health threat globally, with drug‐resistant strains undermining treatment efficacy. We analyzed 126 Mycobacterium tuberculosis (M. tuberculosis) isolates with diverse drug resistance spectra and selected 35 for whole genome sequencing (WGS) using Illumina NextSeq, SMRT PacBio Onso and SMRT PacBio Revio ...
Unarine Matodzi +5 more
wiley +1 more source